 | |
| Clinical data | |
|---|---|
| Trade names | Vascor |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699051 |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Well absorbed |
| Protein binding | 99% |
| Metabolism | Hepatic,CYP3A4-mediated |
| Eliminationhalf-life | 42 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H34N2O |
| Molar mass | 366.549 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Bepridil (trade nameVascor) is andiaminecalcium channel blocker once used to treatangina pectoris. It is no longer sold in the United States.
It is nonselective.[1]
It has been discussed as a possible option in the treatment ofatrial fibrillation.[2]
It has been implicated in causing ventricular arrhythmia (torsades de pointes).
In June 2015 a research paper[3] was published finding bepridil to result in a 100% survival rate for mice exposed toebola during an experiment searching for potential pharmaceutical ebola treatments; indicating its potential use in future ebola research and therapy.[4]
A research paper[5]showed that Bepridil inhibited cytopathogenic effects induced bySARS-CoV-2 in Vero E6 cells and in A549 cells in an in vitro assay.
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byadding missing information. |
